Quality of life in low-income patients with metastatic prostate cancer: Divergent and convergent validity of three instruments

Quality of Life Research

Volumn 8, Issue 5, 1999, Pages 461-470

  Sharp, L K ^a,e   Knight, S J ^a   Nadler, R ^a   Albers, M ^b   Moran, E ^c   Kuzel, T ^a   Sharifi, R ^d   Bennett, C ^a  

^a Inst Hlth Serv Res/Plcy S/S   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Blacks; Metastatic disease; Prostatic neoplasms; Quality of life; Socioeconomic factors

Indexed keywords

AGED; ARTICLE; CANCER PATIENT; HUMAN; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; NEGRO; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PSYCHOMETRY; QUALITY OF LIFE; SOCIOECONOMICS;

AGED; CALIFORNIA; CHICAGO; FACTOR ANALYSIS, STATISTICAL; HUMANS; MALE; NEOPLASM METASTASIS; NORTH CAROLINA; POVERTY; PROSTATIC NEOPLASMS; PSYCHOMETRICS; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS; ROC CURVE;

EID: 0032798731     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008940015696     Document Type: Article

References (53)

1. 1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics. CA: A Cancer Journal for Clinicians 1998; 48: 6-29.
2. 2. McIntosh H. Why do african-american men suffer more prostate cancer? Journal of the National Cancer Institute 1997; 89: 188-189.
3. 3. Merrill RM, Potosky AL, Feuer EJ. Changing trends in US prostate cancer incidence rates. Journal of the National Cancer Institute 1996; 88: 1683-1685.
4. 4. Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trail. British Journal of Urology 1997; 79: 235-246.
5. 5. Daniell HW. Osteoporosis after orchiectomy for prostate cancer. Journal of Urology 1997; 157: 439-444.
6. 6. Graversen PH, Nielson KT, Gasser TC, Corle DK, Madsen PO. Radical prostatectomy versus expectant primary treatment in stages I and II prostatic cancer. Urology 1990; 36: 493-498.
7. 7. Karling P, Hammar M, Varenhorst E. Prevalence and duration of hot flashes after surgical or medical castration in men with prostatic carcinoma. Journal of Urology 1994; 152: 1170-1173.
8. 8. Litwin MS. Measuring health related quality of life in men with prostate cancer. Journal of Urology 1994; 152: 1882-1887.
9. 9. U.S. Department of Health and Human Services. Public Health Service, National Institutes of Health. Quality of life assessment in cancer clinical trials: Report of the Workshop on Quality of Life Research in Cancer Clinical Trials. Prevention and Control, National Cancer Institute, Division of Cancer Prevention and Control, Besthesda, MA, 1990.
10. 10. Heinrich RL, Schag CC, Ganz PA. Behavioral medicine approach to coping with cancer: a case report. Cancer Nursing 1984; 7: 243-247.
11. 11. Schag CA, Heinrich RL. Developing a comprehensive tool: the Cancer Rehabilitation Evaluation System. Oncology 1990; 4: 135-138.
12. 12. Schag CA, Ganz PA, Heinrich RL. Cancer Rehabilitation Evaluation System-Short Form (CARES-SF): a cancer-specific rehabilitation and quality of life instrument. Cancer 1991; 68: 1406-1413.
13. 13. Aaronson NK, Ahmedzai S, Bergman B et al. The European organization for research and treatment of cancer QLQ-C30; A quality of life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute 1993; 85: 365-376.
14. 14. Osoba D, Zee B, Warr D et al. Psychometric properties and responsiveness of the EORTC Quality of Life Questionnaire in patients with breast, ovarian, and lung cancer. Quality of Life Research 1994; 3: 143-154.
15. 15. Cella DF. Manual for Functional Assessment of Cancer Therapy Scales and the Functional Assessment of HIV Infection Scale. Version 3. Rush-Presbyterian Hospital, Chicago, IL, 1994.
16. 16. Cella DF, Tulsky DS, Gray G et al. The Functional Assessment of Cancer Therapy (FACT) scale: development and validation of the general measure. Journal of Clinical Oncology 1993; 11: 570-579.
17. 17. Schipper H, Clinch J, McMurray A, Levitt M. Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. Journal of Clinical Oncology 1984; 2: 472-483.
18. 18. Kirk D. Trials and tribulations in prostatic cancer. British Journal of Urology 1987; 59: 375-379.
19. 19. Kozlowski JM, Ellis WJ, Grayhack J. Advanced prostate cancer: Early versus late endocrine therapy. Urologic Clinics of North America 1991; 18: 15-24.
20. 20. Cassileth BR, Soloway MS, Vogelzang NJ, et al. Patients' choice of treatment in stage D prostate cancer. Urology 1989; 33: 57-62.
21. 21. Albertsen PC. African-Americans and prostate cancer. Cancer Journal of Scientific America 1996; 2: 200-201.
22. 22. Baquet CR, Horm JW, Gibb T. Socioeconomic factors and cancer incidence among blacks and whites. Journal of the National Cancer Institute 1991; 83: 551-557.
23. 23. Bennett CL, Ferreira MR, Davis TC et al. Relation between literacy, race, and stage of presentation among low-income patients with prostate cancer. Journal of Clinical Oncology 1998; 16: 3101-3104.
24. 24. Moul JW, Sestrehenn IA, Connelly RR, et al. Prostate-specific antigen values at the time of prostate cancer diagnosis in African American men. Journal of the American Medical Association 1995; 274: 1277-1281.
25. 25. Krongrad A, Perczek RE, Burke MA, Granville LJ, Lai H, Lai S. Reliability of Spanish translations of select urological quality of life instruments. Journal of Urology 1997; 158: 493-496.
26. 26. Knight SJ, Chmiel JS, Kuzel T et al. Quality of life in metastatic prostate cancer among men of lower socioeconomic status: feasibility and criterion-related validity of three measures. Journal of Urology 1998; 160: 1765-1769.
27. 27. Cassileth BR, Soloway MS, Vogelzang NJ et al. Quality of life and psychosocial status in stage D prostate cancer. Quality of Life Research 1992; 1: 323-330.
28. 28. Tannock I, Gospodarowicz M, Meakin W, Panzarella T, Stewart L, Rider VV. Treatment of metastatic prostate cancer with low-dose prednisone; evaluation of pain and quality of life as pragmatic indices of response. Journal of Clinical Oncology 1989; 7: 590-597.
29. 29. Fossa SD. Quality of life after palliative radiotherapy in patients with hormone-resistant prostate cancer: single institution experience. British Journal of Urology 1994; 74: 345-351.
30. 30. Gonin R, Lloyd S, Cella D. Establishing equivalence between scaled measures of quality of life. Quality of Life Research 1996; 5: 20-26.
31. 31. Sloan JA, Loprinzi CL, Kuross SA et al. Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer. Journal of Clinical Oncology 1998; 16: 3662-3673.
32. 32. Spitzer WO, Dobson AJ, Hall J et al. Measuring the quality of life of cancer patients. Journal of Chronic Disease 1981; 34: 585-597.
33. 33. Ringdal GI, Ringdal K. Testing the EORTC quality of life questionnaire on cancer patients with heterogeneous diagnosis. Quality of Life Research 1993; 2: 129-140.
34. 34. Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta K. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 1997; 50: 920-928.
35. 35. Slevin ML, Plant H, Lynch D, Drinkwater J, Gregory MW. Who should measure quality of life, the doctor or the patient? British Journal of Cancer 1988; 57: 109-112.
36. 36. Donovan K, Sanson-Fisher RW, Redman S. Measuring quality of life in cancer patients. Journal of Clinical Oncology 1989; 7: 959-968.
37. 37. Wood-Dauphinee S, Williams JI. The Spitzer quality-of-life index: Its performance as a measure. In: Osaba D, ed. Effect of Cancer on Quality of Life. Boca Raton, FL: CRC Press, 1991: 169-184.
38. 38. Karnofsky DA, Abelman WH, Craver LF, Burchenal JH. The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948; 1: 634-656.
39. 39. Orr ST, Aisner J. Performance status assessment among oncology patients. Cancer Treatment Reports 1986; 70: 1423-1429.
40. 40. Yates JW, Chalmer B, McKegney FP. Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer 1980; 40: 2220-2224.
41. 41. Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, & guidelines. Journal of Clinical Oncology 1984; 2: 187-193.
42. 42. Campbell DT, Fiske DW. Convergent and discriminant validation by the multitrait-multimethod matrix. Psychological Bulletin 1959; 56: 81-105.
43. 43. Mari JJ, Williams P. A comparison of the validity of two psychiatric screening questionnaires in Brazil, using relative operating characteristic analysis. Psychological Medicine 1985; 15: 651-659.
44. 44. Metz CE. Basic principles of ROC analysis. Seminars in Nuclear Medicine 1978; 8: 283-298.
45. 45. Verger E, Salamero M, Conill C. Can Karnofsky Performance Status be transformed to the Eastern Cooperative Oncology Group scoring scale and vice versa? European Journal of Cancer 1992; 28A, 1328-1330.
46. 46. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristics (ROC) curve. Radiology 1982; 143: 29-36.
47. 47. Fonseca ML, Smith ME, Klein RE, Sheldon G. The Department of Veterans Affairs medical care system and the people it serves. Medical Care 1996; 34: MS9 20.
48. 48. Davis TC, Long SW, Jackson RH et al. Rapid Estimate of Adult Literacy in Medicine: A shortened screening internment. Family Medicine 1993; 25: 391-395.
49. 49. Cronbach LJ. Essentials of Psychological Testing. (5th ed.). New York; Harpercollins, 1990.
50. 50. Nunnally JC. Psychometric Theory, vol. 2. New York: Basic Books, 1978, pp 229-246.
51. 51. DeVellis RF. Scale Development. Theory and Applications, London: Sage, 1991, p 85.
52. 52. Peterson RA. A meta-analysis of Cronbach's coefficient alpha. Journal of Consumer Research 1994; 21: 381-391.
53. 53. Sharp LK. Quality of life in men with metastatic prostate cancer: Psychometric properties of three instruments. Dissertation Abstracts International 1997; 58: 2140.